Transplantation & Cellular Therapy (TCT)

Resolution of serious vaso-occlusive pain crises: Results from the ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for sickle cell disease (SCD; bb1111) gene therapy.

Authors: Walters MC.